Rene Bernards

Rene Bernards appears in our data through filings on Lixte Biotechnology Holdings, Inc. shares, published by SEC (Form 4). In total, 7 filings cover trades dated from 14 November 2022 to 3 October 2023.

The open-market record is one-sided, with 7 purchases worth €86k and not one sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. In 2023 alone, the filings show 4 purchases and no sales.

In size, the median ticket on the buying side is €9,773. Of 5 purchases, 2 formed part of a group of insiders buying within 30 days of each other. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.

On 5 October 2023 came the latest disclosure, an open-market purchase for €13k in Lixte Biotechnology Holdings, Inc. Filings reach the SEC (Form 4) feed a median of 1 day after the trade. Section 16 rules allow two business days to file each Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.